HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met

References

• Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, Biagi E, Tettamanti S, Varani L. 2017. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Ther. 25(8):1933–45.
   PubMed Web of Science ®Google Scholar
• Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, et al. 2016. MET exon 14 mutations in non–small-cell lung cancer are associated with advanced age and stage dependent MET genomic amplification and c-Met overexpression. JCO. 34(7):721–30.
   PubMed Web of Science ®Google Scholar
• Bouattour M, Raymond E, Qin S, Cheng A-L, Stammberger U, Locatelli G, Faivre S. 2018. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 67(3):1132–49.
   PubMed Web of Science ®Google Scholar
• Branella GM, Spencer HT. 2021. Natural receptor- and ligand-based chimeric antigen receptors: strategies using natural ligands and receptors for targeted cell killing. Cells. 11(1):21.
   PubMed Web of Science ®Google Scholar
• Chen C, Gu Y-M, Zhang F, Zhang Z-C, Zhang Y-T, He Y-D, Wang L, Zhou N, Tang F-T, Liu H-J, et al. 2021. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. Oncoimmunology. 10(1):1901434.
   PubMed Web of Science ®Google Scholar
• Czyz M. 2018. HGF/c-MET signaling in melanocytes and melanoma. Int J Mol Sci. 19(12). doi:10.3390/ijms19123844
   Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. 2018. Hepatocellular carcinoma. Lancet. 391(10127):1301–14.
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD, et al. 2015. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res. 3(4):356–67.
   PubMed Web of Science ®Google Scholar
• Fu J, Su X, Li Z, Deng L, Liu X, Feng X, Peng J. 2021. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene. 40(28):4625–51.
   PubMed Web of Science ®Google Scholar
• Greten TF, Lai CW, Li G, Staveley-O’Carroll KF. 2019. Targeted and immune-based therapies For hepatocellular carcinoma. Gastroenterology. 156(2):510–24.
   PubMed Web of Science ®Google Scholar
• Holmes O, Pillozzi S, Deakin JA, Carafoli F, Kemp L, Butler PJG, Lyon M, Gherardi E. 2007. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J Mol Biol. 367(2):395–408.
   PubMed Web of Science ®Google Scholar
• Hong M, Clubb JD, Chen YY. 2020. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 38(4):473–88.
   PubMed Web of Science ®Google Scholar
• Huang X, Guo, J., Li, T., Jia, L., Tang, X., Zhu, J., Tang, Qi, Feng, Z. 2021. c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo. J Biomed Res. 36(1):10–21.
   PubMed Web of Science ®Google Scholar
• Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG. 2021. Trial watch: intratumoral immunotherapy. Oncoimmunology. 10(1):1984677.
   PubMed Web of Science ®Google Scholar
• Jiang W, Li T, Guo J, Wang J, Jia L, Shi X, Yang T, Jiao R, Wei X, Feng Z, et al. 2021. Bispecific c-Met/PD-L1 CAR-T cells have enhanced therapeutic effects on hepatocellular carcinoma. Front Oncol. 11:546586.
   PubMed Web of Science ®Google Scholar
• Kang CH, Kim Y, Lee DY, Choi SU, Lee HK, Park CH. 2021. c-Met-specific chimeric antigen receptor T cells demonstrate anti-tumor effect in c-Met positive gastric cancer. Cancers Basel. 13(22):5738.
   PubMed Web of Science ®Google Scholar
• Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, et al. 2015. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor–modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res. 21(14):3149–59.
   PubMed Web of Science ®Google Scholar
• Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B, Gulei D, Dima D, Tanase A, Einsele H, et al. 2022. Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient? J Hematol Oncol. 15(1):78.
   PubMed Web of Science ®Google Scholar
• Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, et al. 2017. Targeting Alpha-Fetoprotein (AFP)–MHC complex with CAR T-Cell therapy for liver cancer. Clinical Cancer Research. 23(2):478–88.
   PubMed Web of Science ®Google Scholar
• Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. 2021. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 18(5):293–313.
   PubMed Web of Science ®Google Scholar
• Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. 2019. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 15(12):2548–60.
   PubMed Web of Science ®Google Scholar
• Min J, Long C, Zhang L, Duan J, Fan H, Chu F, Li Z. 2022. c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549. Bioengineered. 13(4):9216–32.
   PubMed Web of Science ®Google Scholar
• Mori JI, Adachi K, Sakoda Y, Sasaki T, Goto S, Matsumoto H, Nagashima Y, Matsuyama H, Tamada K. 2021. Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model. Cancer Sci. 112(4):1417–28.
   PubMed Web of Science ®Google Scholar
• Newick K, O’Brien S, Moon E, Albelda SM. 2017. CAR T cell therapy for solid tumors. Annu Rev Med. 68(1):139–52.
   PubMedGoogle Scholar
• Nieba L, Honegger A, Krebber C, Pluckthun A. 1997. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng. 10(4):435–44.
   PubMedGoogle Scholar
• Nishida T, Kataoka H. 2019. Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers Basel. 11(9):1339.
   PubMed Web of Science ®Google Scholar
• Organ SL, Tsao MS. 2011. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 3(1 Suppl):S7–s19.
   PubMedGoogle Scholar
• Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C-X, Zhu Z. 2022. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 41(1):119.
   PubMed Web of Science ®Google Scholar
• Puccini A, Marín-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz H-J, Loupakis F, Battaglin F. 2019. Safety and tolerability of c-MET inhibitors in cancer. Drug Saf. 42(2):211–33.
   PubMed Web of Science ®Google Scholar
• Ritter G, Cohen LS, Williams C, Richards EC, Old LJ, Welt S. 2001. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 61(18):6851–59.
   PubMed Web of Science ®Google Scholar
• Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. 2004. Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor. Embo J. 23(12):2325–35.
   PubMed Web of Science ®Google Scholar
• Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, Li W, Cai C, Xu J, Zhao X. 2019. Eradication of hepatocellular carcinoma by NKG2D-Based CAR-T cells. Cancer Immunol Res. 7(11):1813–23.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 71(3):209–49.
   PubMed Web of Science ®Google Scholar
• Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, et al. 2017. Safety and efficacy of intratumoral injections of Chimeric Antigen Receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res. 5(12):1152–61.
   PubMed Web of Science ®Google Scholar
• Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, Parente-Pereira AC, Whilding LM, van der Stegen SJ, Woodman N, et al. 2017. CAR T-cell immunotherapy of MET-expressing malignant mesothelioma. Oncoimmunology. 6(12):e1363137.
   PubMed Web of Science ®Google Scholar
• Uchikawa E, Chen Z, Xiao G-Y, Zhang X, Bai X-C. 2021. Structural basis of the activation of c-MET receptor. Nat Commun. 12(1):4074.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang R, Zhao L, Zhang X, Xu T, Cui M. 2019. Basing on Upar-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells. Biomed Pharmacother. 117:109173.
   PubMed Web of Science ®Google Scholar
• Wu Y, Jiang S, Ying T. 2016. From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. Expert Opin Biol Ther. 16(12):1469–78.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Zhang X, Tu L, Cao J, Hinrichs CS, Su X. 2022. Size-dependent activation of CAR-T cells. Sci Immunol. 7(74):eabl3995.
   PubMed Web of Science ®Google Scholar
• Yang D, Sun B, Zhang X, Cheng D, Yu X, Yan L, Li L, An S, Jiang H, Lasorella A, et al. 2017. Huwe1 sustains normal ovarian epithelial cell transformation and tumor growth through the histone H1.3-H19 cascade. Cancer Res. 77(18):4773–84.
   PubMed Web of Science ®Google Scholar